enGene Therapeutics (ENGN) Liabilities and Shareholders Equity (2022 - 2026)

enGene Therapeutics (ENGN) has reported Liabilities and Shareholders Equity for 5 consecutive years, with $307.5 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 15.33% year-over-year to $307.5 million; the TTM figure through Apr 2026 stood at $1.1 billion (down 1.68% YoY), while the FY2025 annual figure was $221.5 million, down 28.83% from the prior year.
• Liabilities and Shareholders Equity slipped to $307.5 million in Q2 2026 per ENGN's latest filing, from $337.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $337.1 million in Q1 2026 and bottomed at $23.9 million in Q4 2022.
• Historically, Liabilities and Shareholders Equity has averaged $226.7 million across 5 years, with a median of $266.8 million in 2024.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity surged 263.71% — and 2025, when it decreased 28.83%.
• enGene Therapeutics' Liabilities and Shareholders Equity stood at $23.9 million in 2022, then soared by 263.71% to $87.0 million in 2023, then jumped by 257.84% to $311.2 million in 2024, then fell by 28.83% to $221.5 million in 2025, then soared by 38.86% to $307.5 million in 2026.
• Business Quant data shows ENGN's Liabilities and Shareholders Equity at $307.5 million in Q2 2026, $337.1 million in Q1 2026, and $221.5 million in Q4 2025.